We are not against doctor; KPME Bill is in the interest of poor: Health Minister

Udupi, Apr 2: The Udupi Administration has given its nod to lift and transport watermelons, pineapples, papaya and Mattu Gulla after growers in the district complained that their produce will go waste and start rotting due to the lockdown on account of COVID-19.

In statement issued here on Thursday, Deputy Commissioner G Jagadeesha said that the administration has already held a meeting with wholesale fruit merchants registered with the Agriculture Marketing Produce Committee (APMC).

It has directed these merchants to purchase 35 tonnes of pineapples, 55 tonnes of watermelons and 5,000 bunches of bananas from growers and sell them within the district and also send them to other districts. Such transportation has been exempted from prohibitory orders, he said.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Mangaluru, Jul 7: The government of Kerala has barred movement of daily pass holders — professionals and workers — between Kasaragod district and Karnataka’s Dakshina Kannada district following a spurt in COVID-19 cases.

Kerala Revenue Minister E. Chandrasekaran announced the decision at a meeting on Monday in Kasaragod. Both district administrations had in June issued passes to daily travellers in their districts to travel in connection with their work.

Those from Dakshina Kannada intending to work in Kasaragod have to remain in Kasaragod for 28 days if they wish to continue and those from Kasaragod would have to remain in Dakshina Kannada for 28 days if they wish to continue their work, the Minister said.

Thousands from Kasaragod travel daily to Mangaluru and surrounding areas in connection with their work. Their travel past Talapady check post on NH 66 was facilitated by daily e-passes.

Similarly, many from Dakshina Kannada, particularly doctors and healthcare workers, travel daily to Kasaragod with daily e-passes issued by the Kasaragod administration.